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ABSTRACT
Human mitochondrial transcription factor A (TFAM)
is a multi-functional protein, involved in different
aspects of maintaining mitochondrial genome integ-
rity. In this report, we characterized TFAM and
its interaction with tumor suppressor p53 using
various biophysical methods. DNA-free TFAM is a
thermally unstable protein that is in equilibrium
between monomers and dimers. Self-association
of TFAM is modulated by its basic C-terminal tail.
The DNA-binding ability of TFAM is mainly
contributed by its first HMG-box, while the second
HMG-box has low-DNA-binding capability. We
also obtained backbone resonance assignments
from the NMR spectra of both HMG-boxes of
TFAM. TFAM binds primarily to the N-terminal
transactivation domain of p53, with a Kd of
1.95 0.19kM. The C-terminal regulatory domain of
p53 provides a secondary binding site for TFAM.
The TFAM–p53-binding interface involves both
TAD1 and TAD2 sub-domains of p53. Helices a1
and a2 of the HMG-box constitute the main p53-
binding region. Since both TFAM and p53 binds
preferentially to distorted DNA, the TFAM–p53 inter-
action is implicated in DNA damage and repair. In
addition, the DNA-binding mechanism of TFAM and
biological relevance of the TFAM–p53 interaction
are discussed.
INTRODUCTION
Mitochondria, which possibly have evolved from an
endosymbiotically incorporated organism, have their
own genome. Human mitochondrial genome (mtDNA)
is a circular double-stranded DNA (dsDNA) of
16569bp in length (www.mitomap.org). It encodes 13
proteins that are considered essential sub-units of
mitochondrial respiratory chain, two rRNAs and 22
tRNAs. The rRNAs and tRNAs are recruited to construct
mitochondrial translational machineries, required for syn-
thesis of proteins encoded by mtDNA. Best known for
their role in ATP production via the process of oxidative
phosphorylation (OXPHOS), mitochondria are vital
for an array of fundamental cellular functions
including fatty acid oxidation, biosynthesis of amino
acids and heme, apoptosis and signal transduction.
Maintenance of the mitochondrial genome is naturally
crucial for survival. Mitochondrial dysfunctions are
increasingly being associated with human diseases (1)
such as cancer, diabetes, Parkinson’s disease as well as
cellular senescence (2).
Human mitochondrial transcription factor A (TFAM),
originally cloned as a transcription factor for mtDNA,
is a multi-functional protein (3). Transcription of
mitochondrial genomes initiates from three promoters:
the light strand promoter (LSP) and two heavy strand
promoters (HSP1 and HSP2) that are found in the
1.1kb displacement loop (D-loop) control region of
mtDNA. Transcriptional activation capability of TFAM
is mediated through its high aﬃnity to these sequence-
speciﬁc DNAs and its ability to recruit mitochondrial
RNA polymerase (POLRMT) as well as mitochondrial
transcription factor B (TFBM) (4). In addition, TFAM
serves a role in packaging mtDNA into nucleoid-like
structure and its abundance in mitochondria is correlated
with mtDNA copy number. According to classic strand-
asymmetric model (also termed strand-displacement
model) of mtDNA replication (5–7), transcription is
coupled to replication. TFAM is, therefore, implicated
in mtDNA replication. Accumulating evidences suggest
that TFAM is a DNA damage sensor since it binds
more strongly to oxidatively damaged DNA and cisplatin
adducts. Its interaction with tumor suppressor p53 is
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mtDNA is physiologically more vulnerable compared with
nuclear DNA, in view of its close proximity to OXPHOS
sites. It is considered that  1–5% of mitochondrially
consumed oxygen is converted to reactive oxygen species
(ROS) due to electron leaks from respiratory chain.
In addition, mtDNA is more prone to chemical damage
since lipophilic cations tend to accumulate in mito-
chondrial matrix, facilitated by negative membrane poten-
tial at matrix-side. TFAM has been reported to protect
mtDNA from these oxidative and chemical attacks.
Moreover, TFAM displayed higher aﬃnity to branched
DNA structure (e.g. 4-way junction) and might aﬀect
DNA recombination events.
TFAM belongs to a large and diverse superfamily of
high-mobility group (HMG) protein (9). Within this
superfamily, three structurally distinct classes of HMG
proteins have been deﬁned: HMG–nucleosome-binding
family (HMGN), HMG-AT-hook family (HMGA) and
HMG-box family (HMGB). Mammalian HMG-box con-
taining proteins can further be sub-divided into two
major groups. The ﬁrst group consists of HMGB-type
non-sequence-speciﬁc DNA-binding proteins with two
HMG-box domains and a long highly acidic C-tail (e.g.
HMGB1). The second group is highly diverse and consists
of mostly sequence-speciﬁc proteins having a single
HMG-box and no acidic C-tails (e.g. SRY, SOX).
Nevertheless, there exist proteins that have up to six
copies of the HMG-box domain (e.g. UBF1). As a
HMGB protein, TFAM is unique in that it binds
speciﬁc sequence preferentially, but contains two HMG-
box domains. The gene of TFAM spans about 10kb and
consists of seven exons and six introns (10). Exon 5 can
splice alternatively, resulting in two TFAM isoforms (11).
In this article, we report biophysical characterization of
TFAM and its interaction with tumor suppressor p53. In
addition to examinations of TFAM’s oligomerization
state and thermal stability, we performed solution-based
DNA binding of TFAM using ﬂuorescence spectroscopy
and circular dichroism (CD) spectropolarimetry. For the
ﬁrst time, TFAM was studied using nuclear magnetic res-
onance (NMR). We obtained backbone resonance
assignments from the NMR spectra of both HMG-box
domains of TFAM. We were, therefore, able to map the
p53- and DNA-binding sites on HMG-box domain of
TFAM. Similarly, we located binding region of HMG-
box on p53. The DNA-binding mechanism of TFAM
and biological relevance of TFAM–p53 interaction are
also discussed.
MATERIALS AND METHODS
Nucleic acids
The sequences of single-stranded DNAs (ssDNA) and
dsDNA used in this study were summarized in
Supplementary Table S1. All DNAs were HPLC-puriﬁed
and were purchased from either Sigma Genosys or
Eurogentec.
Cloning and expression of HMG1, HMG2, NEx-HMG2,
TFAM and TFAM-"C
Gene fragments, corresponding to residues 50–118
(HMG1), 155–219 (HMG2), 144–219 (NEx-HMG2), 50–
246 (TFAM) and 50–219 (TFAM-C) of TFAM (NCBI
NP_003192), were PCR-ampliﬁed and cloned into
pET24a-HLTV vector using restriction sites BamHI and
EcoRI. N-terminal protein region (residues 1–49) was pre-
dicted to be mitochondrial targeting sequence (MTS)
using MITOPROT [http://ihg2.helmholtz-muenchen.
de/ihg/mitoprot.html; (12)], and was, therefore, removed
from our protein constructs. For protein expression,
plasmid was freshly transformed into Escherichia coli
C41 (DE3). Cells were grown in 2xTY media supple-
mented with 50mg/ml kanamycin, at 37 C. When OD600
reached 0.5–0.6, 1mM isopropyl b-D-1-thiogalacto-
pyranoside (IPTG) was added to induce protein expres-
sion and temperature was lowered to 25 C. After 24h,
cells were harvested and pellets were frozen in liquid
nitrogen.
Puriﬁcation of HMG1, HMG2, NEx-HMG2,
TFAM and TFAM-"C
HMG1, HMG2 and NEx-HMG2. Cells were thawed at
4 C in buﬀer A [50mM Tris–HCl pH 7.4, 300mM
NaCl, 5mM imidazole, 1% (v/v) 2-mercaptoethanol] sup-
plemented with DNase, RNase and protease inhibitor
(Roche), and were lysed by high-pressure homogenization
(EmulsiFlex-C5, Avestin). After centrifugation, we loaded
supernatant onto HisTrap HP column (GE Healthcare)
pre-equilibrated with buﬀer A. After washing with 5CV
of buﬀer A, protein was eluted with linear gradient
of imidazole (0.005–1M) in buﬀer A. His-tag+lipoyl
domain was cleaved with TEV protease overnight at
4 C. The sample was diluted with buﬀer B [25mM Tris–
HCl pH 7.4, 5mM DTT, 10% (v/v) glycerol] to adjust
NaCl concentration to  100mM and loaded onto
HiTrap Heparin HP column (GE Healthcare) pre-
equilibrated with buﬀer B containing 100mM NaCl.
Upon washing with 5CV of buﬀer B containing 100mM
NaCl, protein was eluted with linear gradient of NaCl (0–
1M) in buﬀer B. Fractions containing protein of interest
were pooled and loaded onto HiLoad 26/60 Superdex 75
column (GE Healthcare) pre-equilibrated with buﬀer C
[25mM Tris–HCl pH 7.4, 150mM NaCl, 5mM DTT,
10% (v/v) glycerol]. All chromatographic steps were per-
formed at 4 C. Protein concentration was estimated using
extinction coeﬃcient of 16960/M/cm.
13C,
15N-labeled
sample for NMR was produced in M9 media using
13C6-
D-glucose and
15NH4Cl as carbon source and nitrogen
source, respectively.
TFAM and TFAM-DC. Both proteins were puriﬁed as
above, with the following modiﬁcations: upon TEV
cleavage, TFAM-containing sample was loaded directly
onto HiTrap Heparin HP column (GE Healthcare) pre-
equilibrated with buﬀer B containing 300mM NaCl. After
washing with 5CV of buﬀer B containing 300mM NaCl,
TFAM was eluted with buﬀer B containing 1 M NaCl.
In the case of TFAM-C, protein sample was diluted with
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TEV cleavage. TFAM-C-containing sample was loaded
onto HiTrap Heparin HP column (GE Healthcare) pre-
equilibrated with buﬀer B containing 150mM NaCl,
followed by washing with 5CV of identical buﬀer.
TFAM-C was eluted with linear gradient of NaCl
(0–1M) in buﬀer B. Both TFAM and TFAM-C were
subsequently subjected to size exclusion using HiLoad
26/60 Superdex 75 column (GE Healthcare) pre-
equilibrated with buﬀer D [25mM Tris–HCl pH 7.4,
300mM NaCl, 5mM DTT, 10% (v/v) glycerol]. Protein
concentrations were estimated using extinction coeﬃcients
of 35410/M/cm (TFAM) and 33920/M/cm (TFAM-C).
Expression and puriﬁcation of N-terminal domain of p53
N-terminal domain of p53 (p53N, residues 1–93) was
expressed and puriﬁed as previously reported (13).
Analytical ultracentrifugation
Equilibrium sedimentation experiments were performed
on a Beckman XL-I ultracentrifuge by using Ti-60 rotor
and 6-sector cells at the following speeds: [35000, 40000
and 45000r.p.m.] (HMG1 and HMG2), [25000, 30000,
35000r.p.m.] (TFAM) and [28000, 30000, 34000r.p.m]
(TFAM-C). Data were collected at 5 C, following
absorbance at 230nm, 280nm and interference. The
sample volume was 110ml and concentrations tested
were 5–400mM. Buﬀer conditions were 25mM Tris–HCl
pH 7.4 and 150mM NaCl. For samples containing
TFAM, 1mM DTT was supplemented. Samples were con-
sidered to be at equilibrium as judged by a comparison of
several scans at each speed. Data were processed and
analyzed by using UltraSpin software, which is available
from our web site (www.mrc-cpe.cam.ac.uk).
CD spectropolarimetry and thermal melting
Thermal stabilities of various protein constructs (HMG1,
HMG2, NEx-HMG2, TFAM and TFAM-C) were
studied through CD spectropolarimetry. Thermostated
JASCO J-815 CD spectropolarimeter was used with
constant nitrogen gas purged. Protein concentration
used was 10–20mM, in buﬀer containing 25mM HEPES
pH 7.4 and 150mM NaCl. For sample containing TFAM,
1mM 1,4-dithioerythritol was supplemented. Thermal
denaturation curves for all proteins were obtained by rec-
ording CD spectra at 222nm, from 2 Ct o9 8  C at a tem-
perature ramp rate of 60 C/h. To study conformational
change of TFAM upon DNA binding, CD spectra of
TFAM were recorded in the absence or presence of
28-bp dsDNA (Supplementary Table S1). Wavelength
scans were performed at 20 C, in 0.2nm steps from 194
to 260nm, in 25mM sodium phosphate pH 7.4, 100mM
KCl and 1mM 1,4-dithioerythritol. The protein con-
centration was 10mM and DNA concentration was
4mM. The spectra recorded were corrected for the
spectra of the buﬀer and of the DNA. All CD measure-
ments were made in quartz cuvette with 1 mm path length.
DNA- or p53N-binding of HMG1, HMG2, NEx-HMG2,
TFAM and TFAM-"C
The binding of various protein constructs (HMG1,
HMG2, NEx-HMG2, TFAM and TFAM-C) to either
ssDNA, dsDNA or p53N was performed by using ﬂuores-
cence anisotropy. Measurements were recorded on
FluoroMax-3 spectroﬂuorimeter (Jobin–Yvon–Horiba)
equipped with a Hamilton Microlab Titrator, at 37 C
(unless otherwise stated) in buﬀer containing 25mM
Tris–HCl pH 7.4, 150mM NaCl and 5mM DTT.
Protein was titrated into a cuvette containing either
1.2-ml ﬂuorescein-labeled DNA [initial concentration
100nM (HMG1, HMG2 and NEx-HMG2) or 25nM
(TFAM and TFAM-C)] or AlexaFluor 546-labeled
p53N (initial concentration 50nM), as described earlier
(13). Excitation/emission wavelengths for ﬂuorescein and
AlexaFluor 546 were 480/530 and 540/569nm, respec-
tively. Fluorescence anisotropy was calculated from the
ﬂuorescence intensities and binding analysis was per-
formed using either a simple 1-state binding isotherm or
Hill equation (13,14).
Intrinsic ﬂuorescence measurements
Intrinsic ﬂuorescence measurements were performed with
a Cary Eclipse ﬂuorescence spectrophotometer (Varian).
Scans were recorded using excitation wavelength of 280
nm and emission wavelength ranged from 300 to 400nm.
Slit widths for both excitation and emission were kept
at 5nm, with a photomultiplier voltage of 900V.
Concentrations of TFAM and/or DNA were 500nM, in
buﬀer containing 25mM Tris–HCl pH 7.4, 150mM NaCl
and 5mM DTT.
NMR spectroscopy
NMR spectra were acquired with a Bruker Avance-
II+700-MHz spectrometer equipped with a 5 mm cryo-
genic inverse probe and single-axis gradients.
NMR protein backbone assignment. Backbone
1H,
13C
and
15N resonance assignments of HMG1 and HMG2
were recorded at sample temperatures of 15 C and 5 C,
respectively. Protein concentration used was 200mMi n
buﬀer containing 25mM Tris–HCl pH 7.4, 150mM
NaCl, 1mM DTT and 5% (v/v) D2O. Sequence-speciﬁc
backbone assignments were achieved using 2D
1H,
15N-
heteronuclear single quantum coherence (HSQC), 3D
HNCO, 3D HN(CA)CO, 3D CBCA(CO)NH, 3D
HNCACB, 3D HN(CO)CA and 3D HNCA. All spectra
were processed and analyzed with TopSpin version 2
(Bruker) and Sparky package (http://www.cgl.ucsf
.edu/home/sparky/), respectively. The automated assign-
ment program MARS was used to initially assign
the backbone resonances (15). Near-complete backbone
resonance assignments were achieved for HMG1
( 97%) and HMG2 ( 88%).
1D
1H-NMR experiment. Eﬀective molecular weights in
solution were estimated by measuring
1HT 2 relaxation
time constants for amide protons, using the 1D-spinecho
method (16). Spectra were recorded for  75mM TFAM
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NaCl, 1mM DTT and 5% (v/v) D2O, at 5 C. T2 estimates
were obtained by comparing peak intensities in spectra
recorded with spin-echo delays of 400ms or 2ms.
HSQC. To map the HMG1-binding site on p53N,
1H,
15N-HSQC spectra were recorded with protein in a
buﬀer of 50mM MES pH 6.8, 100mM NaCl, 5mM
DTT and 5% (v/v) D2Oa t5  C. Concentrations of
15N-
labeled p53N+non-labeled HMG1 were 100mM. For
identifying p53N-binding site or DNA-binding site on
HMG1,
1H,
15N-HSQC spectra were recorded with
protein in a buﬀer of 25mM Tris–HCl pH 7.4, 150mM
NaCl, 1 mM DTT and 5% (v/v) D2Oa t1 5  C. In both
control (
13C,
15N-labeled HMG1) and sample
[(
13C,
15N-labeled HMG1+non-labeled p53N) or
(
13C,
15N-labeled HMG1+non-labeled 28-bp dsDNA)]
runs, concentrations of HMG1, p53N and DNA were
100mM. All spectra were externally referenced based on
the frequency of the water resonance.
Cell lines and confocal immunoﬂuorescence microscopy
Human colon epithelial cells, HCT116 p53
+/+, were
grown and maintained in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM+GlutaMax-1, Invitrogen), supple-
mented with 10% FCS. Cells were sub-cultured at a
ratio of 1:8 in standard 6-well plate and cells were
grown on glass cover slips overnight. Media were
replaced with either fresh DMEM media or DMEM
supplemented with cisplatin (20/50mM, freshly prepared
in DMSO). After 24h, cells were subjected to immuno-
ﬂuorescence staining as described earlier (13). Images were
collected on a BioRad Radiance confocal microscope.
Chemical shift-based homology modeling
Chemical shift database search was performed using
a chemical shift comparison algorithm SimShiftDB
(17,18). SimShiftDB analyses each possible pairing of
the target protein with each template in the database
and retrieves a list of matching proteins, scored by
a measure of statistical signiﬁcance. In addition,
SimShiftDB provides a pair-wise chemical shift alignment
that maps a set of residues from the target protein to a set
of residues from the template structure. We used the
chemical shifts data for TFAM HMG1 to scan the PDB
template database with SimShiftDB. The search retrieved
the structures of UBF1-HMG4 (PDB 1wgf) and TOX-
HMG (PDB 2co9) with highest scores of 15e
–15 and
14e
–14, respectively. A composite alignment derived from
the alignments of the top-scoring templates was used as
an input for Modeller (19,20). Twenty-ﬁve models were
generated. The stereo-chemical qualities of all generated
models were assessed using PROCHECK (21). The
Ramachandran plot shows 98.2% of the residues in the
most-favored region, 1.7% in the additional allowed
region and 0.2% in the disallowed region. Pair-wise struc-
ture superimpositions were performed by using TopMatch
(22). PyMOL (http://www.pymol.org/) was used for visu-
alization of the structures.
RESULTS
Domain architecture of TFAM
TFAM contains two HMG-box domains (Figure 1A).
A basic 36-residue linker connects these tandem HMG-
box domains, followed by a 27-residue carboxyl-terminal
tail that is also rich in basic amino acid residues. In order
to examine the DNA-binding propensity and function
of individual domains, we have created a series of
TFAM deletion constructs (Figure 1A): ‘HMG1’
(residues 50–118, ﬁrst HMG-box domain), ‘HMG2’
(155–219, second HMG-box domain), ‘NEx-HMG2’
(144–219, second HMG-box domain with a partial
linker at its N-terminus), ‘TFAM’ (50–246, full-length
mitochondrial form of TFAM) and ‘TFAM-C’
(50–219, mitochondrial form of TFAM without
C-terminal tail). N-terminal protein region (residues
1–49) was predicted to be MTS using MITOPROT
[http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.html;
(12)] and was, therefore, removed from our protein con-
structs. In other words, proteolytic cleavage site upon
mitochondrial transportation of TFAM was assumed to
be C49jP50 in the present study. Nevertheless, some
research groups regard 42Fj43S as the proteolytic
cleavage site (23,24). Further, experimental evidences
exist indicating that mitochondrial targeting determinants
of TFAM may extend beyond the cleavable MTS (24).
Thus, the precise presequence of TFAM remains to be
clariﬁed. All proteins used in this study were extensively
puriﬁed to near homogeneity, as judged from SDS–
PAGE (Figure 1B). Cell lysate was subjected to DNaseI
Figure 1. (A) A schematic diagram of various TFAM deletion
constructs used in this study. Dashed box indicates region deleted in
the shorter TFAM isoform. (B) SDS–PAGE of various TFAM deletion
constructs on a NuPAGE Novex 4–12% Bis–Tris gel.
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HP column, HiTrap Heparin HP column, HiLoad 26/60
Superdex 75 column) to ensure DNA-free proteins for
biophysical studies.
DNA-free TFAM exists as monomer–dimer in
equilibrium
During the puriﬁcation of HMG1, TFAM and TFAM-
C (Figure 1A), we have observed anomalous elution
proﬁles in size exclusion chromatography (Supplementary
Figure S1). HMG1 was found to have an elution volume
that indicated a size of a tetramer, whereas TFAM and
TFAM-C displayed elution volumes consistent with
sizes of dimers. In both HMG2 and NEx-HMG2
(Figure 1A), the elution volumes showed approximately
sizes of monomers. We have also noticed that elution
volume of TFAM was slightly aﬀected by the ionic
strength of buﬀer used (Supplementary Table S2).
Increased buﬀer’s ionic strength resulted in reduced
protein mobility, and therefore, a delayed elution from
gel ﬁltration column. HMG proteins were named on the
basis of their irregular electrophoretic mobility in
polyacrylamide gels. As a member of HMG proteins, the
observed behavior of TFAM and its deletion constructs
(particularly HMG1 and TFAM-C) in Superdex column
is probably not surprising. Nevertheless, knowing the
stoichiometric state of TFAM is of paramount importance
to understand how TFAM functions in promoter or
mitochondrial DNA (mtDNA) binding. It has been
suggested that TFAM exists as monomer from sedimen-
tation velocity analysis (23) and glycerol gradient sedimen-
tation analysis (25). Kaufman et al. concluded that
TFAM was a dimer from size exclusion chromatography
(albeit an inappropriate methodology for HMG proteins
analyses) and proposed that TFAM dimerization was
likely mediated through the predicted coil–coil domain
that resides within the second HMG-box domain (26).
These disagreements prompted us to use equilibrium sed-
imentation analytical ultracentrifugation (AUC) to une-
quivocally determine the stoichiometry of TFAM and its
deletion constructs. Our results showed that individual
HMG-box domain (HMG1 or HMG2) of TFAM exists
as monomer in solution (Table 1). The data of both
HMG1 and HMG2 were ﬁtted well to single-exponential
models, using partial speciﬁc volume (nB) of 0.7319
(HMG1) or 0.7107 (HMG2) and solvent density (r)o f
1.007 at 5 C (all values were calculated using Sednterp
software). Averaged apparent molecular weights
(Mw,app) of 8.80 and 8.34kDa were obtained for HMG1
and HMG2, respectively. These values correspond to
calculated molecular weights of HMG1 monomer
(Mw=8.63kDa) and HMG2 monomer (Mw=
8.07kDa). Attempt to ﬁt the TFAM data to single-
exponential model was not successful (Figure 2A).
However, the data was ﬁtted well to double-exponential
model using nB=0.7296 and r=1.007 (Figure 2B),
indicating that TFAM is neither a homogeneous
solution of monomer nor dimer. Based on the averaged
Mw,app found (24.31 and 47.15kDa), TFAM exists as
monomer (calculated Mw=23.95kDa) and dimer
(calculated Mw=47.90kDa) in equilibrium. Surprisingly,
TFAM-C was a monomer from our AUC experiments.
Upon ﬁtting to single-exponential model (nB=0.7296
and r=1.007), an averaged Mw,app of 20.91kDa was
acquired, corresponding to monomeric size of TFAM-
C (calculated Mw=20.69kDa). To revalidate these
Table 1. Apparent molecular weights of various TFAM deletion constructs, obtained from equilibrium sedimentation AUC
Single-exponential model Double-exponential model
Apparent Mw (kDa) F
a Apparent Mw (kDa)
of ﬁrst species
F
a Apparent Mw (kDa)
of second species
F
a
HMG1 (Calculated Mw=8.63kDa)
50.0mM 8.84 0.04 1.02 – – – –
200.0mM 8.76 0.01 1.02 – – – –
HMG2 (Calculated Mw=8.07kDa)
5.0mM 8.68 0.05 1.08 – – – –
50.0mM 7.41 0.03 0.86 – – – –
200.0mM 8.94 0.01 1.11 – – – –
400.0mM – – 7.47 0.07 0.93 13.52 0.15 1.68
TFAM (Calculated Mw=23.95kDa)
5.0mM – – 25.29 0.37 1.06 54.46 0.65 2.27
10.0mM – – 25.02 0.75 1.04 43.75 3.29 1.83
50.0mM – – 24.71 0.14 1.03 44.49 0.37 1.86
100.0mM – – 24.78 0.08 1.03 53.02 0.55 2.21
150.0mM – – 22.88 0.30 0.96 42.45 0.88 1.77
189.4mM – – 23.18 0.11 0.97 44.71 0.44 1.87
TFAM-C (Calculated Mw=20.69kDa)
10.0mM 20.76 0.08 1.00 – – – –
50.0mM 20.91 0.03 1.01 – – – –
100.0mM 21.07 0.03 1.02 – – – –
aF=Apprent Mw/calculated Mw.
Data were ﬁtted to either a single-exponential model or a double-exponential model.
Nucleic Acids Research, 2009,Vol.37, No. 20 6769ﬁndings, we derived an eﬀective molecular weight of both
TFAM and TFAM-Ca t5  C from NMR
1HT 2 relax-
ation time constant estimates. Judging from the spectral
proﬁles (number of peaks and peak positions), TFAM and
TFAM-C were structurally indistinguishable, as
expected. Overlapping spectra at diﬀerent   clearly
indicated that TFAM-C, but not TFAM, was homoge-
neous solution (data not shown). Combining data from
size-exclusion, AUC and NMR, we proposed that: (i)
DNA-free TFAM exists as monomer–dimer in equilib-
rium; (ii) self-association of TFAM is mediated through
its C-terminal tail; and (iii) high-mobility of TFAM
observed in size-exclusion is contributed mainly by its
ﬁrst HMG-box domain.
TFAM is thermally unstable
We next examined the thermal stability of TFAM through
circular dichroism. Since TFAM is rich in helical content
from PSIPRED prediction [Supplementary Figure S2;
(27)], we followed the change of ellipticity at 222nm as
temperature was raised from 2 Ct o9 8  C. The reversibil-
ity of thermal denaturation was checked by reheating the
sample (rescan), after cooling the sample to its starting
temperature. Supplementary Figure S3 illustrates the
thermal melting curves of various TFAM deletion
constructs. The data were ﬁtted to a 2-state protein
unfolding model (28). The ﬁt returned the melting
temperatures (Tm, midpoints of transition) of 308.9K
(HMG1), 296.1K (HMG2), 310.9K (TFAM) and
311.3K (TFAM-C) (Table 2). The thermal denaturation
of individual HMG-box domain (HMG1 or HMG2) of
TFAM is fully reversible, although Tm of HMG2 is
12.8K lower than that of HMG1. In the recently pub-
lished X-ray crystal structure of HMG2 [PDB 3fgh;
(23)], the hydrophobic core between helices a1 and a2
contained two amino acids (Y162 and Y200) that had
multiple conformations suggesting a highly dynamic core
that has not been seen in the non-sequence-speciﬁc HMG
structures. The lower Tm of HMG2 thus reﬂects this less
rigid hydrophobic core that is also observed in sequence-
speciﬁc transcription factors in the absence of DNA (e.g.
Sox5 and SRY). Since N- and C-terminal tails (usually
unstructured) of all HMG-boxes lie close together, we
Figure 2. (Upper panels) Equilibrium sedimentation AUC of TFAM (5mM) at speeds of 25000r.p.m. (open circle), 30000r.p.m. (time) and
35000r.p.m (open square). Experiments were conducted at 5 C in 25mM Tris–HCl pH 7.4, 150mM NaCl and 1mM DTT. Data were ﬁtted
to either a single-exponential model (A) or a double-exponential model (B). Curve ﬁts were shown as smooth lines. (Lower panels) Residuals
of curve ﬁts.
Table 2. Transition temperatures (Tm) of CD thermal melting curves
for various TFAM deletion constructs
Up-scan melting
temperature (K)
Re-scan melting
temperature (K)
HMG1 308.9 0.1 308.4 0.1
HMG2 296.1 0.2 296.8 0.2
NEx-HMG2 302.6 0.1 302.0 0.1
TFAM 310.9 0.3 310.5 0.3
TFAM-C 311.3 0.8 310.2 0.5
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of HMG2 would help stabilizing the protein fold
(Supplementary Figure S4). To test this hypothesis, we
created a longer construct of HMG2 (denoted as NEx-
HMG2), in which a partial linker (11 residues) was
added to its N-terminus. In accordance with our predic-
tion, NEx-HMG2 displayed a Tm of 302.6K that was
6.5K higher than Tm of HMG2. Therefore, the linker
region of TFAM plays a role in maintaining the overall
fold, and thus stability, of the second HMG-box domain.
Both TFAM and TFAM-C was slightly more thermal
stable than HMG1. Upon thermal denaturation,
we noticed slight protein aggregation in TFAM and
TFAM-C samples. This would explain why thermal
denaturations of these proteins were not fully reversible,
in contrast to HMG1 and HMG2 (Supplementary Figure
S3). Since Tm of TFAM was similar to those of HMG1
and NEx-HMG2, we believe that the two HMG-box
domains of TFAM unfold independently of one another.
TFAM binds DNA co-operatively and with high aﬃnity
Using ﬂuorescence anisotropy, we performed solution-
based DNA-binding experiments to measure the aﬃnity
of various TFAM deletion constructs to ssDNA and
dsDNA (Table 3). In contrast to radioactivity-based
electrophoretic mobility shift assay (EMSA) that is
commonly employed to study DNA binding of TFAM
qualitatively (23,25,29), ﬂuorescence anisotropy allows
quantitative measurement of DNA aﬃnity. Three types
of DNAs were tested for each protein construct: a 28-bp
dsDNA consisting of TFAM-binding site on human
mtDNA [MITOMAP map locus: MT-TFH (30); map
position: 523–550 (31); denoted as 28-bp dsDNA herein],
a 28-base ssDNA corresponding to the ‘heavy’-strand of
the former dsDNA (28-base ssDNA) and a 50-bp dsDNA
of random sequence (50-bp dsDNA).
The dissociation constant (Kd) of HMG1 for DNA was
temperature-dependent, which is reminiscent of some
DNA-binding proteins for instance ORF56 (32). In the
case of HMG1, Kd measured at three diﬀerent tempera-
tures followed the order of 37 C<20 C<5 C
(Figure 3A), despite the low Tm of HMG1 ( 36 C,
Table 2). We ascribed this observation to the nature of
reversible thermal denaturation of HMG1 (Figure 4A).
At body temperature (37 C), folded HMG1 plausibly
exists in equilibrium with unfolded HMG1 and folded
HMG1 is competent in DNA binding. The presence of
DNA would, therefore, shift the equilibrium in favor of
folded HMG1. For the purpose of comparing the contri-
bution of each TFAM domain to DNA binding, we
decided to conduct our DNA-binding experiments at
physiological conditions namely 37 C and 150mM ionic
strength. In general, DNA-binding data of HMG1 were
ﬁtted well to a simple 1-state binding model. Kd for 28-bp
dsDNA was 1.82mM, which was  2-fold higher than Kd
for 28-base ssDNA (3.81mM) and for 50-bp dsDNA
(3.58mM). On the contrary, HMG2 displayed very weak
DNA-binding capability (Supplementary Figure S5),
corroborating ﬁndings from other research group (23).
This unusual property of HMG2 is probably due to the
presence of a polar residue (N163) in the position typically
Table 3. Binding of DNAs (ssDNA or dsDNA) and p53N (residues 1–93) to various TFAM deletion constructs, measured using ﬂuorescence
anisotropy
Kd (M) (simple one-state model)
a Hill equation
a,b Number of
titrations repeated
Kd (M) Hill constant
HMG1
28-bp dsDNA 1.82 0.06 (10
 6) 1.60 0.14 (10
 6) 1.11 0.09 4
28-base ssDNA 3.81 0.42 (10
 6) 3.33 0.16 (10
 6) 1.08 0.03 3
50-bp dsDNA 3.58 0.14 (10
 6) 2.60 0.19 (10
 6) 1.23 0.05 3
p53N 1.40 0.18 (10
 5) 1.26 0.21 (10
 5) 1.06 0.07 4
HMG2
28-bp dsDNA n.d.
28-base ssDNA n.d.
50-bp dsDNA n.d.
p53N n.d.
TFAM
28-bp dsDNA Poor ﬁt 6.76 0.83 (10
 8) 1.61 0.24 5
28-base ssDNA Poor ﬁt 5.94 0.57 (10
 8) 1.76 0.18 3
50-bp dsDNA Poor ﬁt 8.78 0.40 (10
 8) 2.36 0.09 3
p53N 1.95 0.19 (10
 6) 2.05 0.15 (10
 6) 0.96 0.10 4
TFAM-C
28-bp dsDNA 7.10 0.40 (10
 8) 7.91 0.31 (10
 8) 1.22 0.04 3
28-base ssDNA Poor ﬁt 11.72 0.88 (10
 8) 1.24 0.06 3
50-bp dsDNA Poor ﬁt 11.63 0.67 (10
 8) 1.38 0.11 3
p53N 2.92 0.42 (10
 6) 3.25 0.71 (10
 6) 0.93 0.05 4
aA linear drift term was added to the ﬁtting equation.
bHill equation: [Protein]
h/(Kd
h+[Protein]
h) where h is Hill constant.
DNAs and p53N were labeled with 50-ﬂuorescein or AlexaFluor 546, respectively. Data were ﬁtted to either a simple 1-state model or Hill equation.
All experiments were conducted at 37 C.
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into the minor groove of DNA. Moreover, the region
known to make DNA contacts is completely absent
from the N-terminus of helix a2 in HMG2 (23). When
we aligned and compared TFAMs from various species
(Supplementary Table S3), all HMG-box domains
showed basic pI values except the second HMG-box
domains of Homo sapiens (pI=7.31) and of Mus
musculus (pI=6.88). DNA binding of HMG proteins
usually involves electrostatic interactions, hydrogen
bonds, van der Waals contacts, as well as important
intercalating non-polar residues reside in either helices
a1o ra2 of HMG box. Near-neutral pI of HMG2, there-
fore, could possibly be another explanation of its low-
DNA aﬃnity. Nevertheless, crystal structure of HMG2
clearly revealed the presence of a positively charged
concave surface area that is typically involved in DNA
binding of HMG boxes (23). Hence, we tested DNA
binding of NEx-HMG2, the longer and more stable
HMG2 construct. NEx-HMG2 showed increased DNA
binding compared with HMG2 (Supplementary Figure
S5A; Table 4), although aﬃnity was 10-fold lower than
that of HMG1. We reason that linker enhances DNA
binding of HMG2 by providing additional DNA
contacts (33,34). Thus, the second HMG-box domain of
TFAM is a potential DNA binder with its DNA-binding
capacity being modulated by the linker region. A smaller
isoform of TFAM mRNA was found in most human
tissue with a 96-base deletion. Since the ﬁfth exon is iden-
tical to the 96 bases skipped in this shorter mRNA, this
isoform is concluded to be generated by alternative
splicing (11). Interestingly, the region of deletion corres-
ponds to the second HMG-box domain (E148!Q179,
32 residues; Figure 1A) that showed weak DNA binding.
To ﬁt data from TFAM and TFAM-C experiments,
1-state-binding model could not be applied. These data,
however, were ﬁtted well to the Hill equation indicating
co-operativity in DNA binding (Figures 3B and 3C).
Compared with HMG1, TFAM showed signiﬁcantly
higher aﬃnity to 28-bp dsDNA (27-fold), 28-base
ssDNA (64-fold) and 50-bp dsDNA (41-fold). When the
C-terminal tail was truncated, DNA-binding aﬃnity was
reduced  1.2–2-folds. This result is consistent with
ﬁndings from EMSA [2.2-fold reduction; (23)]. It is
worth a note that positive co-operativity was reduced in
all three DNAs tested, after removal of the TFAM C-tail
(1.61!1.22 in 28-bp dsDNA, 1.76!1.24 in 28-base
ssDNA and 2.36!1.38 in 50-bp dsDNA). Since the C-
tail modulates self-association of TFAM, we postulate
that TFAM binds as a dimer on DNA resulting in a
more positive co-operativity (Figure 4B). The exact mech-
anism and interface of TFAM self-association, of course,
requires further studies. TFAM dimerization upon DNA
binding was also supported by evidences from non-contact
atomic force microscopy (26) and from EMSA (23).
Mutational analysis of TFAM revealed that the C-tail is
important for speciﬁc DNA recognition and essential for
transcriptional activation (35,36). The C-tail is necessary
to bind mitochondrial transcription factor B (37) for
eliciting transactivation. Here, we demonstrated that the
C-tail facilitates TFAM dimerization on DNA. Ohgaki
Figure 3. Binding titration proﬁles of various TFAM deletion
constructs with ﬂuorescein-labeled dsDNA. Experiments were con-
ducted in 25mM Tris–HCl pH 7.4, 150mM NaCl and 5mM DTT.
(A) Proﬁles of HMG1 at three diﬀerent temperatures, 5 C (diamond),
20 C (triangle) and 37 C (square). (B) Proﬁle of TFAM at 37 C. (C)
Proﬁle of TFAM-Ca t3 7  C.
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binding activity of TFAM by three orders of magnitude
using surface plasmon resonance (SPR) kinetic analysis
(38). We have observed non-speciﬁc interaction between
TFAM and sensor chip (data not shown). The discrepancy
between our data and those reported by Ohgaki et al. is
likely contributed by various factors including diﬀerent
DNAs used (sequence and length), non-speciﬁc TFAM–
sensorchip interaction and ﬁtting model (1:1 Langmuir
binding model was used in the report from Ohgaki et al.).
TFAM contains two tryptophan residues in each
HMG-box domain (W88 and W107 in the ﬁrst domain,
W189 and W218 in the second domain). Of these, W88,
W189 and W218 are strictly conserved among TFAMs
from various species (Supplementary Figure S6).
Figure 5A shows the intrinsic ﬂuorescence spectra of
TFAM, in the absence and presence of DNA. Excitation
at 280nm gave an emission maximum at 344 nm, implying
that some of these tryptophan residues are solvent
exposed. Upon binding DNA, emission maxima were
blue-shifted to  338nm and the ﬂuorescence emissions
were reduced 31–52%. Thus, these conserved tryptophan
residues are involved in stabilizing protein–nucleic acid
complexes, plausibly via stacking interactions with the
nucleotide bases of DNA or intercalating into DNA
grooves. The binding of TFAM to DNA has also an
eﬀect on its secondary structure, as evaluated by UV
CD spectropolarimetry (Figure 5B). The CD-spectrum
of TFAM–DNA complex shows a decrease in optical
ellipticity in the spectral region 208–235nm, compared
with that of DNA-free TFAM. The decrease is indicative
of formation of additional a-helical region or type-II
b-turn. We did not observe signiﬁcant change in the CD
spectrum >240nm, which would otherwise indicate DNA
conformational change from B-DNA to either A-DNA or
Z-DNA. Although HMG-box is widely recognized to
induce DNA deformations (bending and unwinding)
upon DNA binding, this feature is not apparent in our
CD measurements using 28-bp dsDNA (Supplementary
Table S1). The magnitude of DNA deformation induced
by HMG-box is likely DNA-sequence or DNA-length
dependent.
Taken together, our solution-based DNA-binding data
conform to the reported biological roles of TFAM as a
transcriptional activator (preference towards sequence-
speciﬁc DNA) and a mtDNA-packaging factor (high
aﬃnity for non-sequence-speciﬁc DNA).
TFAM binds p53N
Tumor suppressor p53 has previously been demonstrated
to interact with DNA-binding proteins. Salient examples
include human mitochondrial single-stranded DNA-
binding protein [HmtSSB; (13)], replication protein A
[RPA; (39)] and transcriptional co-activator PC4 (40),
Table 4. Binding of 5’-ﬂuorescein-labeled DNAs (linear or bulged) to various TFAM deletion constructs, measured using ﬂuorescence anisotropy
Kd (M) (simple one-state model) Hill equation
a Number of titrations
repeated
Kd (M) Hill constant
TFAM
Normal DNA-S Poor ﬁt 4.13 0.59 (10
–7) 1.26 0.14 5
Bulged DNA-S Poor ﬁt 1.64 0.17 (10
–7) 1.24 0.12 3
Normal DNA-L
b Poor ﬁt 2.14 0.33 (10
–8) 2.04 0.19 3
Bulged-DNA-L
b Poor ﬁt 3.15 1.08 (10
–8) 1.85 0.21 3
NEx-HMG2
Normal-DNA-L 2.92 0.34 (10
–5) 2.69 0.32 (10
–5) 1.09 0.16 3
HMG2
Normal DNA-L Estimated to be >40mM
aHill equation: [Protein]
h/(Kh
d+[Protein]
h) where h is Hill constant.
bA linear drift term was added to the ﬁtting equation.
Data were ﬁtted to either a simple 1-state model or Hill equation. All experiments were conducted at 10 C.
Figure 4. (A) Proposed DNA-binding mechanism of HMG1. Folded HMG1 exists in equilibrium with unfolded HMG1 and folded HMG1 is
competent in DNA binding. The presence of DNA would shift the equilibrium in favor of folded HMG1. (B) Schematic DNA-binding models of
TFAM and TFAM-C. The C-tail modulates self-association of TFAM and promotes TFAM dimer formation upon DNA binding. This accounts
for more positive co-operativity in DNA binding of TFAM, in comparison to TFAM-C.
Nucleic Acids Research, 2009,Vol.37, No. 20 6773via N-terminal transactivation domain of p53. It has also
been reported that p53 interacts with HMG proteins,
including HMGB1 (41) and TFAM (8). On the basis of
these previous ﬁndings, we hypothesized that TFAM-
binding site on p53 resides within its transactivation
domain. By using ﬂuorescence anisotropy, we assayed
TFAM for binding to an AlexaFluor 546-labeled p53N
(residues 1–93) at physiological ionic strength and our
hypothesis was indeed veriﬁed (Figure 6). The binding
data of all protein constructs tested were ﬁtted well to a
simple 1-state binding model (Table 3), and aﬃnity
towards p53N followed the order of TFAM (1.95mM) >
TFAM-C (2.92mM) > HMG1 (14mM). To localize the
binding interface on p53N, we recorded 2D
1H,
15N-HSQC
NMR spectra of
15N-labeled p53N (100mM) in the
absence and presence of unlabeled HMG1 (100mM). In
Figure 7, free
15N-labeled p53N spectrum (red) was
overlaid with the HMG1-bound spectrum (blue). p53N
interacts clearly with HMG1 through an extended inter-
face. Large chemical shift perturbations were mainly
localized in three regions: region I (residues 18–26),
region II (residues 30–38) and region III (residues 40–
56). The p53 transactivation domain is subdivided into
two loosely deﬁned sub-domains (42), TAD1 (residues
1–40) and TAD2 (residues 41–61). We found that
HMG1 interacts simultaneously with TAD1 and TAD2,
similar to HmtSSB (13) and transcriptional co-activator
p300 (43). Both sub-domains contains a -X-X--
motif (where =hydrophobic amino acid and X=any
amino acid) that been shown to be important in many
protein–protein interactions [Supplementary Figure S7;
(44)]. Our NMR experiment demonstrated that
p53–HMG1 interaction involves these two motifs
(F19-W23 in TAD1 and I50-F54 in TAD2), signifying
the involvement of hydrophobic interaction in stabiliz-
ing p53–HMG1 complex. Further, HMG1-binding site
identiﬁed in our NMR study coincides with p53N
regions that were known to form helical structures upon
complex formation [i.e. helix 1 (S15-P27), helix 2
(D41-M44) and helix 3 (P47-T55); Supplementary Figure
S7] (39,45). We believe that electrostatic interactions
contribute substantially to p53N–HMG1 complex forma-
tion, in view of acidic nature of p53N (pI=3.47) and
basic nature of HMG1 (pI=9.99).
Figure 5. (A) Intrinsic ﬂuorescence emission spectra of TFAM in the
absence (red) and presence of 28-bp dsDNA (blue), 28-bp ssDNA (dark
yellow) and 50-bp dsDNA (magenta), at excitation wavelength of
280nm. Experiments were conducted at 25 C in 25mM Tris–HCl pH
7.4, 150mM NaCl and 5mM DTT. Concentrations of both TFAM and
DNAs were 500nM. Control spectra without TFAM were also
recorded: buﬀer (black), 28-bp dsDNA in buﬀer (green), 28-bp
ssDNA in buﬀer (purple) and 50-bp dsDNA in buﬀer (cyan). (B)U V
CD spectra of 10mM DNA-free TFAM (continuous line) and TFAM
complexed with 4mM 28-bp dsDNA (broken line), corrected for the
background of DNA alone in buﬀer. Experiments were conducted
at 20 C, in 25mM sodium phosphate pH 7.4, 100mM KCl and
1mM 1,4-dithioerythritol.
Figure 6. Binding titration proﬁles of HMG1 (diamond), TFAM
(triangle) and TFAM-C (square) with AlexaFluor 546-labeled
p53N. Experiments were conducted at 37 C, in 25mM Tris–HCl pH
7.4, 150mM NaCl and 5mM DTT.
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and p53 required either one of the two HMG-box
domains and residues 363–376 of p53 (8), based on pull-
down assays. We, therefore, assayed TFAM for binding to
a ﬂuorescein-labeled p53C (residues 362–393) at physio-
logical ionic strength, using ﬂuorescent anisotropy. All
protein constructs tested (TFAM, HMG2, NEx-HMG2)
showed weak binding to p53C (Supplementary Figure
S5B). We ascribe this low aﬃnity to basic nature of
p53C (pI=9.61) and suggest that the C-tail of p53 is
possibly a secondary binding site of TFAM. Protein
partners having two diﬀerent binding sites on p53 have
previously been reported. These include S100 [binds
transactivation and tetramerization domains of p53;
(46)] and Mdm2 [binds transactivation and core domains
of p53; (47)]
Both TFAM and p53 bind distorted DNA preferentially
TFAM has previously been demonstrated to bind
preferentially to oxidatively damaged DNA (e.g. 8-oxo-
7,8-dihydroguanine), cisplatinated-DNA and DNA
lesions induced by chemical carcinogens (e.g. N-acetoxy-
acetylaminoﬂuorene), using EMSA assays (48,49). To
further investigate this preference quantitatively, we used
ﬂuorescence anisotropy to study binding of TFAM to two
diﬀerent DNAs. One of these was a linear DNA with 12
bp (denoted as Normal-DNA-S). The other was a bulged
DNA containing a dA2 bulge, with its sequence being
identical to the previous one (Bulged-DNA-S). We chose
to study bulged DNA because it is structurally analogous
to UV-induced pyrimidine dimers (naturally occurring
DNA lesions) and cisplatinated-DNA (adducts induced
in vivo by anticancer drug cisplatin). Both pyrimidine
dimer and cisplatination induce DNA bends of magnitude
comparable with the bulge-induced bends (50,51).
Therefore, the study of bulged DNA is biologically
relevant. As shown in Figure 8A and Table 4, TFAM
bound distorted DNA preferentially. Kd for Bulged-
DNA-S (164nM) was 2.5-fold lower, compared with
that for Normal-DNA-S (413nM). Nevertheless, this
preference was not evident when we used DNAs that
were four times longer in length (Normal-DNA-L and
Bulged-DNA-L). Interestingly, p53 displayed the same
preference (Figure 8B), although Kd of p53 for short
DNA was much higher. Taken together, p53–TFAM
interaction may play a signiﬁcant role in DNA damage
and repair. Further, our data provided direct evidence
that TFAM can indeed bind DNA as short as 12bp,
in agreement with estimation from Pellegrini et al.
that TFAM was present at a ratio of one molecule
per  10–12bp of mtDNA (52). This estimation was
based on quantitative western and Southern blot
analyses, using protein–DNA isolated from mouse liver
mitochondria.
NMR backbone resonance assignments of HMG1
and HMG2
For the purpose of mapping p53N-binding site on
HMG-box domain, we assigned the backbone resonances
in the NMR spectra of both HMG1 and HMG2.
13C,
15N-
labeled HMG1 and
13C,
15N-labeled HMG2 samples
provided well-dispersed NMR spectra at 15 C and 5 C,
respectively (Figure 9). Low temperatures were chosen to
populate natively folded HMG1 and HMG2, in view of
their low Tm (Supplementary Figure S3; Table 2). This
allowed determination of >85% of the backbone reso-
nance assignments from HMG1 (97%, Supplementary
Table S4) and HMG2 (87%, Supplementary Table S5),
as described in ‘Materials and Methods’ section. Even
though the spectrum of HMG2 was recorded at 5 C,
we noticed a large number of sharp overlapping
resonances in the random coil region of the spectrum
(
1HN 8.0–8.5ppm). Therefore, HMG2 is partially
structured in the DNA-free protein, which explains its
lower thermal stability (Supplementary Figure S3;
Table 2). The intrinsic disorder in DNA-free HMG-box
was also documented for SRY box (53) and LEF-1 box
(54). To localize p53N-binding site, we acquired 2D
1H,
15N-HSQC NMR spectra of
13C,
15N-labeled HMG1
(100mM) in the absence and presence of unlabeled p53N
(100mM). In Figure 10A, we presented the overlay spectra
Figure 7. 2D
1H,
15N-HSQC NMR spectra of
15N-labeled p53N
(residues 1–93, 100mM) in the absence (red) and presence of 100mM
of HMG1 (blue). Spectra were recorded at 5 C in 50mM MES pH 6.8,
100mM NaCl, 5mM DTT and 5% (v/v) D2O.
Nucleic Acids Research, 2009,Vol.37, No. 20 6775of free HMG1 (red) and p53N-bound HMG1 (blue).
Large chemical shift perturbations were mapped to
regions of high-helical propensity, as predicted by
PSIPRED (Supplementary Figure S7). It appears that
p53N interacts extensively with helices a1 and a2
(Supplementary Figure S7). The
1H,
15N-HSQC spectrum
of HMG1–DNA complex (1:1 ratio, 100mM of each) is
shown in Figure 10B (green). Drastic chemical shift
changes have occurred for the HMG1 resonances,
reﬂecting either extensive DNA-binding interface or
conformational change. When we used a ratio of 2.5
HMG1 to 1 DNA, most peaks disappeared in the
1H,
15N-HSQC spectrum (Supplementary Figure S8).
This is a common phenomenon when high-molecular
weight complexes are formed. In other words, there were
more than one HMG-box bound to a single DNA
molecule, when HMG-box was present in excess (a
‘pigeonhole principle’ applies in this case). Of note, we
observed perturbation of tryptophan side chain
resonances upon DNA binding (
1HN 10–12 ppm, indole
side-chain region). This indicates that tryptophan side
chains were positioned in a diﬀerent environment,
corroborating our intrinsic ﬂuorescence measurement
(Figure 5A).
Comparison of HMG1 homology model with
HMG2 structure
Using NMR chemical shift data of HMG1, we created a
homology model of this HMG-box domain (see ‘Materials
and Methods’ section). HMG1 adopts canonical HMG-
box fold and consists of an extended region (residues 50–
55) and three helices (residues 56–71, 77–90, 93–116) that
are approximately orthogonal to one another (Figure
11A). The N-terminal extended region packs against the
C-terminal helix a3. The core, formed at the intersection
of the three helices, comprises residues Phe60, Trp88 and
Tyr99 which are surrounded by Tyr57, Ile84, Leu91 and
Lys96. In addition, the orientation of helix a1 toward
helix a2 is stabilized by several hydrophobic contacts
formed by residues Leu65, Phe68 and Leu80 (Figure
12A). Structural comparison of HMG1 model and
HMG2 structure (3fgh) reveals that these two HMG-
box domains are very similar and superpose with a root
mean square deviation of 2.1A ˚ (Figure 11A). Most of
the residues forming the hydrophobic core, at the intersec-
tion between the three helices, are invariant. The
only exception is that Phe60 and Ile84 of HMG1 are
replaced by Tyr165 and Val185 in HMG2, respectively
(Figure 12). Despite the global similarity, several
diﬀerences between HMG1 and HMG2 structures are
apparent. These include the region connecting helices
a1 and a2, and the length of helix a1 (Figure 11B).
HMG2 contains a four-residue deletion resulting in a
shorter helix a1. None of the residues forming contacts
between helices a1 and a2 are conserved. Leu65, Phe68
and Leu80 of HMG1 are replaced by Phe170, Ala173
and Lys181 in HMG2, respectively. Thus, the orientation
of helix a1 towards helix a2 in HMG2 is determined
by the hydrophobic contacts between the aliphatic
portion of Lys181 and the side-chains of Phe170 and
Ala173. Although the large-to-small substitution of
Phe68!Ala173 is partly compensated by the substitution
of Leu65!Phe170, this rearrangement causes a small
displacement of helix a1 relative to the axes of helices a2
and a3. The electrostatic potential surface comparison
of HMG1 and HMG2 shows that the overall charge of
the DNA-binding interface is preserved (Figure 13). The
displacement of helix a1 in HMG2, however, widens
the concave DNA-binding interface and could be a poten-
tial reason for the weaker DNA-binding property of
this domain (Supplementary Figure S5A; Table 4).
Modeling of the N-terminal linker of NEx-HMG2 (11
residues) suggests that some of the hydrophobic residues
in this region might have a role in the stabilization of
HMG-box, as observed experimentally (Supplementary
Figure 8. Binding titration proﬁles of TFAM (A) and p53 (B) with
ﬂuorescein-labeled linear DNA (circle) or bulged DNA (triangle).
Experiments were conducted at 10 C, in 25mM Tris–HCl pH 7.4,
150mM NaCl and 5mM DTT.
6776 Nucleic Acids Research, 2009,Vol.37, No. 20Figure S3). In particular, Leu152 could form a
hydrophobic contact with Trp218 and thus orient the
main-chain carbonyl group of Gly153 in a position
suitable for hydrogen bond formation (Supplementary
Figure S4). Since this 11-residue linker is highly positively
charged, we would expect that the linker contributes to
DNA anchoring, as observed in other HMG-box contain-
ing proteins (33,34).
Figure 9. 2D
1H,
15N-HSQC NMR spectra of HMG1 (A) and HMG2 (B), acquired at 15 C and 5 C, respectively. Non-assigned peaks were labeled
with NA. Peaks corresponding to side chain amides were not labeled. Both spectra were recorded with 100mM protein in 25mM Tris–HCl, 150mM
NaCl, 1 mM DTT and 5% (v/v) D2O.
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Structure–function relationships of TFAM
TFAM is a multi-functional protein, involved in various
aspects of mtDNA integrity maintenance: transcription,
replication, nucleoid formation, DNA protection, DNA
repair and damage sensing (3). In part, its functional
diversity is a result of TFAM’s domain architecture
(Figure 1A). TFAM is constructed by two tandem
HMG-box domains, which are connected by a basic
36-residue linker. To the C-terminus of the second
HMG-box domain, a 27-residue tail is attached, that is
also rich in basic amino acid residues. In order to investi-
gate the DNA-binding propensity and function of each
domain of TFAM, we adopted a ‘divide-and-conquer’
strategy by creating a series of TFAM deletion constructs
as depicted in Figure 1A. Using equilibrium sedimentation
AUC (Table 1), we showed that HMG1 and HMG2 were
monomers in solution. On the contrary, TFAM exists
as monomer–dimer in equilibrium (Figure 2) and its self-
association is modulated by the basic C-tail. This ﬁnding
was validated by 1D
1H-NMR spectra of TFAM and
TFAM-C (data not shown). The anomalous elution
proﬁle of TFAM in size-exclusion chromatography
Figure 10. (A)2 D
1H,
15N-HSQC NMR spectra of
13C,
15N-labeled HMG1 (100mM) in the absence (red) and presence of 100mM of p53N (blue).
(B)2 D
1H,
15N-HSQC NMR spectra of
13C,
15N-labeled HMG1 (100mM) in the absence (red) and presence of 100 mM of DNA (green). All spectra
were recorded at 15 C in 25mM Tris–HCl pH 7.4, 150mM NaCl, 1mM DTT and 5% (v/v) D2O.
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HMG1. This ‘high mobility’ is a consequence of asymmet-
ric nature of TFAM and interaction between highly
charged TFAM and chromatographic material. TFAM
is thermally unstable, with a Tm close to body temperature
(37.7 C) determined from CD spectropolarimetry
(Supplementary Figure S3; Table 2). HMG1 displayed
similar Tm (35.7 C), while HMG2 showed substantially
lower Tm (23.0 C). The thermal instability of DNA-free
HMG2 well reﬂects its less rigid hydrophobic core (23)
and its intrinsic disorder that we observed in 2D
1H,
15N-
HSQC spectrum of HMG2 (Figure 9B). The linker
region enhances stability of HMG2, possibly by providing
additional contacts with C-end of HMG2 and thus
Figure 11. Comparison of HMG-box domains (HMG1 and HMG2) of TFAM. (A) Stereo views of structural superposition of HMG2 (3fgh, red)
overlaid with a bundle of 25 HMG1 models (black). Images were generated using PYMOL. (B) Structure-based sequence alignment of HMG1 and
HMG2. Secondary structure elements were shown above the protein sequences. Invariant residues between HMG1 and HMG2 were highlighted in
yellow.
Figure 12. (A) Hydrophobic core of HMG1 model, with Y57, F60, I84, W88, L91, K96 and Y99 indicated. (B) Hydrophobic core of HMG2 (3fgh)
with Y162, Y165, V185, W189, L192, K197 and Y200 indicated. Both images were generated using PYMOL.
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conﬁguration (23). From our solution-based DNA-
binding experiments using ﬂuorescent anisotropy,
TFAM binds DNA co-operatively with nanomolar
aﬃnity and a preference towards sequence-speciﬁc DNA.
Despite its low Tm, TFAM maintains high aﬃnity towards
DNA at 37 C. This is possible since thermal unfolding of
TFAM is almost completely reversible (Supplementary
Figure S3). The presence of DNA shifts the equilibrium
towards folded HMG-box that is competent in DNA
binding (Figure 4A). The C-tail contributes signiﬁcantly
to positive co-operativity of TFAM’s DNA binding,
which is linked to its capability of inducing TFAM
self-association (Figure 4B). The C-tail removal reduces
DNA-binding aﬃnity by a factor of 1.2–2, consistent
with in vivo data reported (36). When TFAM-C was
expressed at levels comparable to those of endogenous
TFAM in HeLa cells, mtDNA increased two folds, sug-
gesting that TFAM-C was as competent in maintaining
mtDNA as endogenous TFAM. TFAM-C, however,
lost its transcriptional activity in vitro (36). TFAM
dimerization at promoter region might be biologically
signiﬁcant to elicit its transcriptional activity. Interes-
tingly, isolated HMG2 is a weak DNA binder as
opposed to HMG1. This unusual behavior of HMG2
can be attributed to various reasons: the lack of
DNA intercalating residue, missing region known to
make DNA contacts, and near neutral pI (Table S3).
Linker region compensates this inability of HMG2
(Figure S5A), likely by providing additional DNA
contacts (33,34). It is worth noting that the highly
conserved tryptophan residues (Supplementary Figure
S6) are involved in DNA binding, as judged from intrinsic
ﬂuorescence measurement (Figure 5A) and 2D
1H,
15N-
HSQC spectrum of HMG1–DNA complex (Figure 10B).
Finally, DNA binding induces conformational change of
TFAM (Figure 5B). The decrease in optical ellipticity at
spectral region 208–235nm indicates formation of addi-
tional a-helical region or type-II b-turn, possibly at intrin-
sic disorder region resides within HMG2 or linker region.
Biological implications of TFAM–p53 interaction
Tumor suppressor p53 is involved in a multitude of
cellular functions including cell-cycle arrest, apoptosis,
senescence, DNA damage and repair (55). For the ﬁrst
time, we showed that TFAM interacts primarily with
N-terminal transactivation domain of p53 (p53N,
residues 1–93, Figures 6, 7 and 10A). C-terminal regula-
tory domain of p53 (p53C, residues 362–393) provides
a secondary binding site for TFAM (Supplementary
Figure S5B).
p53N is inherently devoid of any tertiary structure.
Nevertheless, a pre-existing amphipathic helix (T18-L26)
and two nascent turns (turn I: M40-M44 and turn II: D48-
W53, both weakly amphipathic) were found in unbound
p53N, using heteronuclear multi-dimensional NMR spec-
troscopy (45). These local secondary structures are
selectively formed by functionally critical and positionally
conserved hydrophobic residues (hydrophobic antennae,
e.g. F19, L22, W23 and L26 in p53N) present in several
acidic transactivation domains (AADs) (45). Such local
structures are general features of AADs and may represent
‘speciﬁcity determinants’ that are important for
transcriptional activity (56). We speculate that the struc-
tural transitions associated with p53N upon TFAM
binding involve both (i) tightening of the pre-existing
helix into a stable helix and (ii) conversion of the two
nascent turns (turns I and II) into an amphipathic helix.
The later coil-to-helix transition is either due to structural
restraints imposed by TFAM or induced by hydrophobic
cores of HMG-boxes. The fact that the overall helical
content of several AADs increases upon addition of
hydrophobic solvents that might mimic the hydrophobic
environment of a target protein supports such a possibility
(45). In p53N upon TFAM binding, we picture formation
of two helices (S15-L32 and Q38-D57) with a symmetrical
linker (S33-S37) between them. This would also explain
the chemical shift perturbations we observed in p53N
(Figure 7; Supplementary Figure S7). We believe that
p53N docks into the positively charged DNA-binding
cleft of HMG-box (Figure 13), mimicking single-
stranded DNA structurally (39,40). Amphipathic helices
of p53N could plausibly orient in a way that hydrophilic
sides are exposed to solvent and hydrophobic sides are
buried. In this orientation, HMG-box–p53 complex is
stabilized by electrostatic interactions of the negatively
charged side chains of p53N and the positively charged
side chains of HMG-box, as well as hydrophobic
interactions between the buried surface of p53N helix
Figure 13. Electrostatic surface potential plots of HMG1 model and
HMG2 (3fgh), generated with PYMOL. Regions of positive potential
were colored in blue, and regions of negative potential were colored in
red. (A) Front views showing DNA-binding interfaces. (B) Back views.
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(Y57, F60, W88). Therefore, HMG-box represents a struc-
tural entity endowing dual aﬃnity (i) for acidic,
amphipathic helices and (ii) for DNAs. The aforemen-
tioned speculations would certainly require experimental
validations, e.g. by solving the crystal structure of HMG-
box–p53 complex.
Similar to RPA–p53 interaction (57), TFAM–p53 inter-
action could possibly involve two distinct areas of p53
(p53N and p53C, Figure 6 and Supplementary Figure
S5B) simultaneously. This is likely facilitated by the
presence of DNA. In the absence of DNA, p53 displays
an elongated cross-shaped structure with a pair of loosely
coupled core domain dimers at the ends, which are
accessible for binding to DNA or protein partners (58).
The core domains in this ‘open conformation’ can close
around a DNA to form a compact complex, resulting in a
‘close conformation’ (58). Further, DNA induces TFAM
dimerization that is modulated by TFAM C-terminal tail
(Figure 4B). In a possibly compact TFAM–p53–DNA
ternary complex, one would envisage the feasibility of
‘two-point interaction’.
We believe that TFAM–p53 interaction is biologically
relevant. The naturally oxidative environment of mito-
chondria and lack of an eﬃcient DNA repair mechanism
render mtDNA highly susceptible to mutations, and these
mutations are frequently associated with a variety of
human diseases (1). Since both TFAM and p53 binds
preferentially distorted DNA (Figure 8, Table 4),
TFAM–p53 interaction is implicated in DNA damage
and repair. In this same vein, we recently reported that
HmtSSB (a mtDNA packaging factor and sub-unit of
mtDNA replisome) binds to p53N via an extended
binding interface, with dissociation constant of 12.7
( 0.7mM) (13). HmtSSB enhances intrinsic 30-50 exo-
nuclease activity of p53 (59), particularly in hydrolysing
8-oxo-7,8-dihydro-20-deoxyguanosine (8-oxodG) present
at 30-end of DNA (13). Our data suggest that p53 is
involved in maintaining integrity of mitochondrial
genome, in line with ﬁndings from other group (60).
Remarkably, p53 null mouse and p53 knockdown
human primary ﬁbroblasts were shown to exhibit
mtDNA depletion, decreased mitochondrial mass and
membrane potential, reduced protein level of both
ribonucleotide reductase p53R2 sub-unit and TFAM, as
well as disruption of cellular ROS homeostasis (61).
Altogether, p53 has a direct impact on mitochondrial
homeostasis. Although Kd of TFAM to p53N falls in
micromolar range (1.95 0.19mM), TFAM is a copious
protein within mitochondria (62). In human HeLa cells,
TFAM is 1700-fold more abundant than mtDNA (63).
Pellegrini et al. estimated that TFAM was present at a
ratio of one molecule per  10–12bp of mtDNA (52).
Further, TFAM was up-regulated in cisplastin-treated
KB human epidermoid cancer cells (8). It is important
to note that mitochondrial p53 isolated from ML1,
HCT116 and RKO cells, after short term genotoxic
stress, were phosphorylated on Ser 6, Ser 9, Ser 15, Ser
20, Ser 37 and Ser 46 (64). These serine residues were
located within TAD1 and TAD2 sub-domains of p53,
the identiﬁed binding interface between p53 and TFAM
from NMR (Figure 7 and Supplementary Figure S7).
Since phosphorylation increases negative charge of
p53N, the aﬃnity between TFAM–p53 in vivo is likely
higher than value obtained from in vitro measurement.
Relative aﬃnities of the N-terminal transactivation
domain of p53 for transcription co-activator p300
domains or PC4 were reported to be regulated by phos-
phorylation, and phosphorylation generally enhances
binding aﬃnity (40,65). Last but not least, mitochondrial
translocation of p53 would result in its eventual
compartmentalization within these organelles, leading to
increased local p53 concentration in mitochondria.
Protein traﬃc upon DNA damage
As a predominantly nuclear protein, p53 lacks MTS.
Nevertheless, mitochondrial localization of p53 was
observed after cisplatin treatment [(8) and in present
study; Supplementary Figure S9]. The mechanism by
which p53 is transported into mitochondria remains,
however, unclear. Being an important chemotherapeutics,
cisplatin is best recognized as a DNA damaging agent and
the cytotoxicity of cisplatin has generally been attributed
to its ability to form inter- and intra-strand DNA
crosslink. While most investigations of cisplatin pharma-
cology focussed on cisplatin/nuclear DNA adducts, only
1% of intracellular platinum is bound to nuclear DNA.
The remaining majority of the intracellular drug is avail-
able for targeting nucleophilic sites on other molecules,
including phospholipids, cytosolic, cytoskeletal and
membrane proteins, RNA, or even mtDNA (66). The
voltage-dependant anion channel (VDAC, also termed
mitochondrial porin) contains two cysteines and two
methionines, in total four potential targets for platinum
binding. VDAC has been shown to form cisplatin/protein
adducts, resulting in permeability alteration of mitocho-
ndrial membrane (66). Likewise, cisplatin could possibly
change the permeability of nuclear envelope that
was noticeable in Supplementary Figure S9. Since p53
was up-regulated after drug treatment, p53 observed
in perinuclear mitochondria might be a consequence
of passive diﬀusion (Supplementary Figure S9).
Remarkably, it has been demonstrated that TFAM
overexpression and impairment of its mitochondrial tar-
geting could result in nuclear accumulation of this protein
(24). A putative bipartite nuclear localization sequence
(two clusters of positively charged residues separated by
11 amino acids) was found in HMG1. Nuclear TFAM was
found to confer cytoprotection against chemotherapeutic
drugs e.g. etoposide, camptothecin and cisplatin.
Mitochondrial localization of p53 and nuclear accumula-
tion of TFAM raise the possibility that p53 and TFAM
were examples of ‘eclipsed distribution’ (67). Upon DNA
damage, protein traﬃc is likely bi-directional (p53: nuclei
! mitochondria, TFAM: mitochondria ! nuclei).
CONCLUSION
In the present study, we characterized interaction between
TFAM and p53. Biophysical measurements, in conjunc-
tion with cellular biology methods, provide a systematic
Nucleic Acids Research, 2009,Vol.37, No. 20 6781platform to study the physical and functional interactions
between these two proteins in vitro. The biological rele-
vance of this binding in vivo would require more in-depth
investigations, in view of the complex multi-functional
roles of both TFAM and p53.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENT
We thank Prof. Hans Spelbrink (University of Tampere,
Finland) for providing the gene encoding TFAM,
Dr. Robert Sade for useful discussion, Caroline M. Blair
and Fiona Sait for technical assistance.
FUNDING
The European Union FP6 Proteomage (to A.R.F. and
T.S.W.); MRC Career Development Fellowship (to
T.S.W.). Funding for open access charge: Medical
Research Council, UK.
Conﬂict of interest statement. None declared.
REFERENCE
1. Copeland,W.C. (2008) Inherited mitochondrial diseases of DNA
replication. Ann. Rev. Med., 59, 131–146.
2. Van Remmen,H. and Jones,D.P. (2009) Current thoughts on the
role of mitochondria and free radicals in the biology of aging.
J. Gerontol. A Biol. Sci. Med. Sci., 64, 171–174.
3. Kang,D. and Hamasaki,N. (2005) Mitochondrial transcription
factor A in the maintenance of mitochondrial DNA: overview of its
multiple roles. Ann. NY Acad. Sci., 1042, 101–108.
4. Bonawitz,N.D., Clayton,D.A. and Shadel,G.S. (2006) Initiation and
beyond: multiple functions of the human mitochondrial
transcription machinery. Mol. Cell, 24, 813–825.
5. Clayton,D.A. (2003) Mitochondrial DNA replication: what we
know. IUBMB Life, 55, 213–217.
6. Falkenberg,M., Larsson,N.G. and Gustafsson,C.M. (2007) DNA
replication and transcription in mammalian mitochondria. Ann.
Rev. Biochem., 76, 679–699.
7. Robberson,D.L. and Clayton,D.A. (1972) Replication of
mitochondrial DNA in mouse L cells and their thymidine kinase -
derivatives: displacement replication on a covalently-closed circular
template. Proc. Natl Acad. Sci. USA, 69, 3810–3814.
8. Yoshida,Y., Izumi,H., Torigoe,T., Ishiguchi,H., Itoh,H., Kang,D.
and Kohno,K. (2003) P53 physically interacts with mitochondrial
transcription factor A and diﬀerentially regulates binding to
damaged DNA. Cancer Res., 63, 3729–3734.
9. Stros,M., Launholt,D. and Grasser,K.D. (2007) The HMG-box:
a versatile protein domain occurring in a wide variety of
DNA-binding proteins. Cell Mol. Life Sci., 64, 2590–2606.
10. Reyes,A., Mezzina,M. and Gadaleta,G. (2002) Human
mitochondrial transcription factor A (mtTFA): gene structure
and characterization of related pseudogenes. Gene, 291, 223–232.
11. Tominaga,K., Hayashi,J., Kagawa,Y. and Ohta,S. (1993) Smaller
isoform of human mitochondrial transcription factor 1: its wide
distribution and production by alternative splicing. Biochem.
Biophys. Res. Commun., 194, 544–551.
12. Claros,M.G. and Vincens,P. (1996) Computational method to
predict mitochondrially imported proteins and their targeting
sequences. Eur. J. Biochem., 241, 779–786.
13. Wong,T.S., Rajagopalan,S., Townsley,F.M., Freund,S.M.,
Petrovich,M., Loakes,D. and Fersht,A.R. (2009) Physical and
functional interactions between human mitochondrial single-
stranded DNA-binding protein and tumour suppressor p53.
Nucleic Acids Res., 37, 568–581.
14. Weinberg,R.L., Veprintsev,D.B. and Fersht,A.R. (2004)
Cooperative binding of tetrameric p53 to DNA. J. Mol. Biol., 341,
1145–1159.
15. Jung,Y.S. and Zweckstetter,M. (2004) Mars – robust automatic
backbone assignment of proteins. J. Biomol. NMR, 30, 11–23.
16. Anglister,J., Grzesiek,S., Ren,H., Klee,C.B. and Bax,A. (1993)
Isotope-edited multidimensional NMR of calcineurin B in the
presence of the non-deuterated detergent CHAPS. J. Biomol. NMR,
3, 121–126.
17. Ginzinger,S.W. and Coles,M. (2009) SimShiftDB: local
conformational restraints derived from chemical shift similarity
searches on a large synthetic database. J. Biomol. NMR, 43,
179–185.
18. Ginzinger,S.W., Graeupl,T. and Heun,V. (2007) SimShiftDB:
chemical-shift-based homology modeling. In Hochreiter,S. and
Wagner,R. (eds), Bioinformatics research and development,
Vol. 4414. Heidelberg, Springer Berlin, pp. 357–370.
19. Eswar,N., Webb,B., Marti-Renom,M.A., Madhusudhan,M.S.,
Eramian,D., Shen,M.Y., Pieper,U. and Sali,A. (2006) Comparative
protein structure modeling using modeller. Curr. Protoc.
Bioinformatics, Chapter 5, Unit 5.6.
20. Sali,A. and Blundell,T.L. (1993) Comparative protein modelling by
satisfaction of spatial restraints. J. Mol. Biol., 234, 779–815.
21. Laskowski,R.A., MacArthur,M.W., Moss,D.S. and Thornton,J.M.
(1993) PROCHECK: a program to check the stereochemical quality
of protein structures. J. Appl. Cryst., 26, 283–291.
22. Sippl,M.J. and Wiederstein,M. (2008) A note on diﬃcult structure
alignment problems. Bioinformatics, 24, 426–427.
23. Gangelhoﬀ,T.A., Mungalachetty,P.S., Nix,J.C. and Churchill,M.E.
(2009) Structural analysis and DNA binding of the HMG domains
of the human mitochondrial transcription factor A. Nucleic Acids
Res., 37, 3153–3164.
24. Pastukh,V., Shokolenko,I., Wang,B., Wilson,G. and Alexeyev,M.
(2007) Human mitochondrial transcription factor A possesses
multiple subcellular targeting signals. FEBS J., 274, 6488–6499.
25. Fisher,R.P. and Clayton,D.A. (1988) Puriﬁcation and
characterization of human mitochondrial transcription factor 1.
Mol. Cell Biol., 8, 3496–3509.
26. Kaufman,B.A., Durisic,N., Mativetsky,J.M., Costantino,S.,
Hancock,M.A., Grutter,P. and Shoubridge,E.A. (2007) The
mitochondrial transcription factor TFAM coordinates the assembly
of multiple DNA molecules into nucleoid-like structures. Mol. Biol.
Cell, 18, 3225–3236.
27. Jones,D.T. (1999) Protein secondary structure prediction based on
position-speciﬁc scoring matrices. J. Mol. Biol., 292, 195–202.
28. Fersht,A.R. (1998) Structure and mechanism in protein science:
a guide to enzyme catalysis and protein folding. W. H. Freeman and
Company, New York, pp. 511–513.
29. Ikeda,S., Sumiyoshi,H. and Oda,T. (1994) DNA binding properties
of recombinant human mitochondrial transcription factor 1. Cell
Mol. Biol. (Noisy-le-grand), 40, 489–493.
30. Ruiz-Pesini,E., Lott,M.T., Procaccio,V., Poole,J.C., Brandon,M.C.,
Mishmar,D., Yi,C., Kreuziger,J., Baldi,P. and Wallace,D.C. (2007)
An enhanced MITOMAP with a global mtDNA mutational
phylogeny. Nucleic Acids Res., 35, D823–D828.
31. Fisher,R.P., Topper,J.N. and Clayton,D.A. (1987) Promoter
selection in human mitochondria involves binding of a transcription
factor to orientation-independent upstream regulatory elements.
Cell, 50, 247–258.
32. Lipps,G., Stegert,M. and Krauss,G. (2001) Thermostable and
site-speciﬁc DNA binding of the gene product ORF56 from the
Sulfolobus islandicus plasmid pRN1, a putative archael plasmid
copy control protein. Nucleic Acids Res., 29, 904–913.
33. Lnenicek-Allen,M., Read,C.M. and Crane-Robinson,C. (1996)
The DNA bend angle and binding aﬃnity of an HMG box
increased by the presence of short terminal arms. Nucleic Acids
Res., 24, 1047–1051.
34. Stros,M. (2001) Two mutations of basic residues within the
N-terminus of HMG-1 B domain with diﬀerent eﬀects on DNA
supercoiling and binding to bent DNA. Biochemistry, 40,
4769–4779.
6782 Nucleic Acids Research, 2009,Vol.37, No. 2035. Dairaghi,D.J., Shadel,G.S. and Clayton,D.A. (1995) Addition
of a 29 residue carboxyl-terminal tail converts a simple HMG
box-containing protein into a transcriptional activator. J. Mol.
Biol., 249, 11–28.
36. Kanki,T., Ohgaki,K., Gaspari,M., Gustafsson,C.M., Fukuoh,A.,
Sasaki,N., Hamasaki,N. and Kang,D. (2004) Architectural role
of mitochondrial transcription factor A in maintenance of human
mitochondrial DNA. Mol. Cell Biol., 24, 9823–9834.
37. McCulloch,V. and Shadel,G.S. (2003) Human mitochondrial
transcription factor B1 interacts with the C-terminal activation
region of h-mtTFA and stimulates transcription independently of
its RNA methyltransferase activity. Mol. Cell Biol., 23, 5816–5824.
38. Ohgaki,K., Kanki,T., Fukuoh,A., Kurisaki,H., Aoki,Y.,
Ikeuchi,M., Kim,S.H., Hamasaki,N. and Kang,D. (2007) The
C-terminal tail of mitochondrial transcription factor a markedly
strengthens its general binding to DNA. J. Biochem., 141, 201–211.
39. Bochkareva,E., Kaustov,L., Ayed,A., Yi,G.S., Lu,Y.,
Pineda-Lucena,A., Liao,J.C., Okorokov,A.L., Milner,J.,
Arrowsmith,C.H. et al. (2005) Single-stranded DNA mimicry in the
p53 transactivation domain interaction with replication protein A.
Proc. Natl Acad. Sci. USA, 102, 15412–15417.
40. Rajagopalan,S., Andreeva,A., Teufel,D.P., Freund,S.M. and
Fersht,A.R. (2009) Interaction between the transactivation domain
of p53 and PC4 exempliﬁes acidic activation domains as
single-stranded DNA mimics. J. Biol. Chem., 284, 21728–21737.
41. Jayaraman,L., Moorthy,N.C., Murthy,K.G., Manley,J.L.,
Bustin,M. and Prives,C. (1998) High mobility group protein-1
(HMG-1) is a unique activator of p53. Genes Dev., 12, 462–472.
42. Chang,J., Kim,D.H., Lee,S.W., Choi,K.Y. and Sung,Y.C. (1995)
Transactivation ability of p53 transcriptional activation domain
is directly related to the binding aﬃnity to TATA-binding protein.
J. Biol. Chem., 270, 25014–25019.
43. Teufel,D.P., Freund,S.M., Bycroft,M. and Fersht,A.R. (2007) Four
domains of p300 each bind tightly to a sequence spanning both
transactivation subdomains of p53. Proc. Natl Acad. Sci. USA, 104,
7009–7014.
44. Lee,C.W., Arai,M., Martinez-Yamout,M.A., Dyson,H.J. and
Wright,P.E. (2009) Mapping the interactions of the p53
transactivation domain with the KIX domain of CBP (dagger).
Biochemistry, 48, 2115–2124.
45. Lee,H., Mok,K.H., Muhandiram,R., Park,K.H., Suk,J.E.,
Kim,D.H., Chang,J., Sung,Y.C., Choi,K.Y. and Han,K.H. (2000)
Local structural elements in the mostly unstructured transcriptional
activation domain of human p53. J. Biol. Chem., 275, 29426–29432.
46. van Dieck,J., Fernandez-Fernandez,M.R., Veprintsev,D.B. and
Fersht,A.R. (2009) Modulation of the oligomerization state of p53
by diﬀerential binding of proteins of the S100family to p53
monomers and tetramers. J. Biol. Chem., 284, 13804–13811.
47. Yu,G.W., Rudiger,S., Veprintsev,D., Freund,S., Fernandez-
Fernandez,M.R. and Fersht,A.R. (2006) The central region of
HDM2 provides a second binding site for p53. Proc. Natl Acad.
Sci. USA, 103, 1227–1232.
48. Pietrowska,M., Kolodziejczyk,I. and Widlak,P. (2006)
Mitochondrial transcription factor A is the major protein in rodent
hepatocytes that recognizes DNA lesions induced by N-acetoxy-
acetylaminoﬂuorene. Acta. Biochim. Pol., 53, 777–782.
49. Yoshida,Y., Izumi,H., Ise,T., Uramoto,H., Torigoe,T.,
Ishiguchi,H., Murakami,T., Tanabe,M., Nakayama,Y., Itoh,H.
et al. (2002) Human mitochondrial transcription factor A binds
preferentially to oxidatively damaged DNA. Biochem. Biophys. Res.
Commun., 295, 945–951.
50. Aboul-ela,F., Murchie,A.I., Homans,S.W. and Lilley,D.M. (1993)
Nuclear magnetic resonance study of a deoxyoligonucleotide duplex
containing a three base bulge. J. Mol. Biol., 229, 173–188.
51. Dornberger,U., Hillisch,A., Gollmick,F.A., Fritzsche,H. and
Diekmann,S. (1999) Solution structure of a ﬁve-adenine bulge loop
within a DNA duplex. Biochemistry, 38, 12860–12868.
52. Pellegrini,M., Asin-Cayuela,J., Erdjument-Bromage,H., Tempst,P.,
Larsson,N.G. and Gustafsson,C.M. (2009) MTERF2 is a
nucleoid component in mammalian mitochondria. Biochim.
Biophys. Acta, 1787, 296–302.
53. Stott,K., Tang,G.S., Lee,K.B. and Thomas,J.O. (2006) Structure of
a complex of tandem HMG boxes and DNA. J. Mol. Biol., 360,
90–104.
54. Love,J.J., Li,X., Chung,J., Dyson,H.J. and Wright,P.E. (2004) The
LEF-1 high-mobility group domain undergoes a disorder-to-order
transition upon formation of a complex with cognate DNA.
Biochemistry, 43, 8725–8734.
55. Romer,L., Klein,C., Dehner,A., Kessler,H. and Buchner,J. (2006)
p53–a natural cancer killer: structural insights and therapeutic
concepts. Angew. Chem. Int. Ed. Engl., 45, 6440–6460.
56. Ptashne,M. and Gann,A. (1997) Transcriptional activation by
recruitment. Nature, 386, 569–577.
57. Bochkareva,E., Belegu,V., Korolev,S. and Bochkarev,A. (2001)
Structure of the major single-stranded DNA-binding domain of
replication protein A suggests a dynamic mechanism for DNA
binding. EMBO J., 20, 612–618.
58. Tidow,H., Melero,R., Mylonas,E., Freund,S.M., Grossmann,J.G.,
Carazo,J.M., Svergun,D.I., Valle,M. and Fersht,A.R. (2007)
Quaternary structures of tumor suppressor p53 and a speciﬁc p53
DNA complex. Proc. Natl Acad. Sci. USA, 104, 12324–12329.
59. Mummenbrauer,T., Janus,F., Muller,B., Wiesmuller,L., Deppert,W.
and Grosse,F. (1996) p53 Protein exhibits 30-to-50 exonuclease
activity. Cell, 85, 1089–1099.
60. Bakhanashvili,M., Grinberg,S., Bonda,E., Simon,A.J., Moshitch-
Moshkovitz,S. and Rahav,G. (2008) p53 in mitochondria enhances
the accuracy of DNA synthesis. Cell Death Diﬀer., 15, 1865–1874.
61. Lebedeva,M.A., Eaton,J.S. and Shadel,G.S. (2009) Loss of p53
causes mitochondrial DNA depletion and altered mitochondrial
reactive oxygen species homeostasis. Biochim. Biophys. Acta., 1787,
328–334.
62. Alam,T.I., Kanki,T., Muta,T., Ukaji,K., Abe,Y., Nakayama,H.,
Takio,K., Hamasaki,N. and Kang,D. (2003) Human mitochondrial
DNA is packaged with TFAM. Nucleic Acids Res., 31, 1640–1645.
63. Takamatsu,C., Umeda,S., Ohsato,T., Ohno,T., Abe,Y., Fukuoh,A.,
Shinagawa,H., Hamasaki,N. and Kang,D. (2002) Regulation of
mitochondrial D-loops by transcription factor A and
single-stranded DNA-binding protein. EMBO Rep., 3, 451–456.
64. Nemajerova,A., Erster,S. and Moll,U.M. (2005) The post-
translational phosphorylation and acetylation modiﬁcation proﬁle
is not the determining factor in targeting endogenous stress-induced
p53 to mitochondria. Cell Death Diﬀer., 12, 197–200.
65. Teufel,D.P., Bycroft,M. and Fersht,A.R. (2009) Regulation by
phosphorylation of the relative aﬃnities of the N-terminal
transactivation domains of p53 for p300 domains and Mdm2.
Oncogene, 28, 2112–2118.
66. Cullen,K.J., Yang,Z., Schumaker,L. and Guo,Z. (2007)
Mitochondria as a critical target of the chemotheraputic agent
cisplatin in head and neck cancer. J. Bioenerg. Biomembr., 39,
43–50.
67. Regev-Rudzki,N. and Pines,O. (2007) Eclipsed distribution: a
phenomenon of dual targeting of protein and its signiﬁcance.
Bioessays, 29, 772–782.
Nucleic Acids Research, 2009,Vol.37, No. 20 6783